Literature DB >> 24657717

Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England.

Albert Jan van Hoek1, Carmen L Sheppard2, Nick J Andrews3, Pauline A Waight3, Mary P E Slack2, Timothy G Harrison2, Shamez N Ladhani3, Elizabeth Miller3.   

Abstract

BACKGROUND/AIMS: In April 2010 the 7-valent pneumococcal conjugate vaccine (PCV7) was replaced by the 13-valent PCV. We investigated pneumococcal carriage in children eligible for PCV7 or PCV13 and their household contacts.
METHODS: Eligible families in Hertfordshire and Gloucester were identified and a nasopharyngeal swab obtained from consenting household members between July 2012 and March 2013. Samples were cultured for Streptococcus pneumoniae and serotyped by standard methods. For each serotype the ratio of its prevalence in invasive pneumococcal disease (IPD) to its carriage prevalence (case:carrier ratio, CCR) was calculated. Results were compared with previous carriage studies in 2001/2002 and 2008/2009, before and after PCV7 introduction.
RESULTS: 217 households were included. Among <5-year olds 47.7% (95% confidence interval 41.8-53.5) were carrying a pneumococcus compared with 51.0% (95% CI: 44.0-58.0) in 2008/2009 and 48.4% (95% CI: 44.1-52.7) in 2001/2002. The odds of carrying a PCV7 serotype was significantly reduced in 2008/2009 (0.07, 95% CI: 0.03-0.16) and 2012/2013 (0.01 95% CI: 0.00-0.07) relative to 2001/2002, while the odds of carrying any of the extra six PCV13 serotypes increased after PCV7 introduction (1.38, 95%CI: 0.73-2.59) but declined significantly after PCV13 introduction (0.05, 95%CI: 0.01-0.37). The CCRs for the frequently carried serotypes were relatively low, with the highest CCR observed for serotypes 7F, 19A, 3, 8, and 33F. Across the three carriage studies, CCR estimates were stable for nearly all serotypes.
CONCLUSION: Carriage of additional PCV13 serotypes has rapidly reduced post-PCV13 introduction in both vaccinated and unvaccinated individuals with a continued decline in transmission of PCV7 serotypes. Carriage rates in children remain unchanged, but the low CCRs of replacing serotypes would be expected to further reduce overall IPD across all age groups.
Copyright © 2014. Published by Elsevier Ltd.

Entities:  

Keywords:  Carriage; Colonisation; Conjugate vaccine; Herd immunity; Nasopharynx; Pneumococcus; Post-PCV13; Streptococcus pneumoniae; Vaccine impact

Mesh:

Substances:

Year:  2014        PMID: 24657717     DOI: 10.1016/j.vaccine.2014.03.017

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  65 in total

1.  Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital.

Authors:  Enrigue Chacon-Cruz; R M Rivas-Landeros; M L Volker-Soberanes
Journal:  Ther Adv Vaccines       Date:  2014-11

2.  Preventing non bacteremic pneumococcal pneumonia in older adults: historical background and considerations for choosing between PCV13 and PPV23.

Authors:  David S Fedson
Journal:  Hum Vaccin Immunother       Date:  2014-04-14       Impact factor: 3.452

3.  Other age groups than children need to be considered as carriers of Streptococcal pneumoniae serotypes.

Authors:  Hans-Christian Slotved
Journal:  Hum Vaccin Immunother       Date:  2016-06-20       Impact factor: 3.452

Review 4.  Prevention of Invasive Pneumococcal Disease: Problems Emerged After Some Years of the 13-Valent Pneumococcal Conjugate Vaccine Use.

Authors:  Nicola Principi; Giuseppe Di Cara; Ilaria Bizzarri; Chiara Isidori; Paola Borgia; Costanza Mignini; Marco Saponara; Alberto Argentiero; Susanna Esposito
Journal:  Curr Infect Dis Rep       Date:  2018-01-24       Impact factor: 3.725

5.  A longitudinal study of streptococcus pneumoniae carriage in healthy children in the 13-valent pneumococcal conjugate vaccine era.

Authors:  Chiara Mameli; Valentina Fabiano; Laura Daprai; Giorgio Bedogni; Marino Faccini; Maria Laura Garlaschi; Francesca Penagini; Dario Dilillo; Erminio Torresani; Maria Gramegna; Gian Vincenzo Zuccotti
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel.

Authors:  Shalom Ben-Shimol; Noga Givon-Lavi; David Greenberg; Ron Dagan
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

Review 7.  Herd effects of child vaccination with pneumococcal conjugate vaccine against pneumococcal non-invasive community-acquired pneumonia: What is the evidence?

Authors:  Cornelis H van Werkhoven
Journal:  Hum Vaccin Immunother       Date:  2016-12-12       Impact factor: 3.452

8.  Prevalence of nasopharyngeal pneumococcal colonization in children and antimicrobial susceptibility profiles of carriage isolates.

Authors:  Julie Y Zhou; Megan Isaacson-Schmid; Elizabeth C Utterson; Elizabeth M Todd; Michelle McFarland; Janardan Sivapalan; Joan M Niehoff; Carey-Ann D Burnham; S Celeste Morley
Journal:  Int J Infect Dis       Date:  2015-09-03       Impact factor: 3.623

9.  Potential carrier priming effect in Australian infants after 7-valent pneumococcal conjugate vaccine introduction.

Authors:  Mohamed Tashani; Sanjay Jayasinghe; Zitta B Harboe; Harunor Rashid; Robert Booy
Journal:  World J Clin Pediatr       Date:  2016-08-08

10.  Emerging Streptococcus pneumoniae Strains Colonizing the Nasopharynx in Children After 13-valent Pneumococcal Conjugate Vaccination in Comparison to the 7-valent Era, 2006-2015.

Authors:  Ravinder Kaur; Janet R Casey; Michael E Pichichero
Journal:  Pediatr Infect Dis J       Date:  2016-08       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.